Fierce Pharma
NOVEMBER 14, 2024
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks to a key patient survival win.
MedCity News
NOVEMBER 14, 2024
Merck is acquiring global rights to a bispecific antibody from LaNova Medicines that blocks two cancer targets, PD-1 and VEGF. The deal comes one day after BioNTech announced an $800 million acquisition that gives it full rights to a molecule in this hot class of cancer drug candidates. The post Merck Is Paying $588M for Potential Successor to Cancer Drug Juggernaut Keytruda appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
NOVEMBER 14, 2024
As sales of Novo Nordisk’s GLP-1 drugs for diabetes and obesity continue to soar, the Danish drugmaker is once again adjusting its insulin production priorities. | Citing 'capacity constraints,' Novo Nordisk plans to transition its human insulin—which is currently sold in pens and vials—to vials only. The decision is playing a part in a broader discussion around equitable access to diabetes treatments in less-wealthy countries.
Pharmaceutical Technology
NOVEMBER 14, 2024
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a programmed death-ligand 1 and vascular endothelial growth factor A-targeting bispecific antibody.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Pharma
NOVEMBER 14, 2024
The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy has already been approved to treat AADC deficiency in Europe and the U.K., among other countries, where it's branded as Upstaza.
MedCity News
NOVEMBER 14, 2024
Prior authorization is a sore subject for payers and providers. So what if it went away? In a recent fireside chat hosted by MedCity News, Don Antonucci, CEO of Providence Health Plan, shared his thoughts. The post Video: What Would Happen If Prior Authorization Went Away? appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
NOVEMBER 14, 2024
In an interview, Rabah talked about the promise of AI, where it can have the most impact, while also responding to the IRA and high drug prices in the United States. The post CEO of Otsuka North America: Are We Getting better access with AI? appeared first on MedCity News.
Fierce Pharma
NOVEMBER 14, 2024
Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued that the company did not lose compliance oversight in China amid local authorities' investigations into the drugmaker's senior executives. AZ and Daiichi Sankyo have refiled their TROP2 antibody-drug conjugate with the FDA.
MedCity News
NOVEMBER 14, 2024
The PTC Therapeutics gene therapy, Kebilidi, treats an enzyme deficiency that affects the body’s ability to produce dopamine, a neurotransmitter important for motor control. FDA approval for the product comes two years after it won its first regulatory approvals in Europe. The post PTC Therapeutics Wins First FDA Approval for a Gene Therapy Dosed Directly Into the Brain appeared first on MedCity News.
pharmaphorum
NOVEMBER 14, 2024
If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York startup Metsera.After emerging from stealth with a $290 million first round in April, the biotech has added another $215 million to its coffers via a Series B led by Wellington Management and Venrock Healthcare Capital Partners, taking the total raised by the company over $500 million in just seven months.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
MedCity News
NOVEMBER 14, 2024
As our industry continues its path toward value-based care, evolving payer models, and increasingly stringent regulations, revenue cycle processes will become even more complex. Providers can prepare by following these steps. The post Unlocking Hidden Revenue: Transforming RCM Challenges into Financial Wins appeared first on MedCity News.
Pharmaceutical Technology
NOVEMBER 14, 2024
Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.
MedCity News
NOVEMBER 14, 2024
By conducting audits, embracing new technologies and switching products, labs can dramatically reduce plastic waste without sacrificing life-saving discoveries. The post Every Lab Can Go Greener With These Key Steps appeared first on MedCity News.
pharmaphorum
NOVEMBER 14, 2024
GSK's multiple myeloma therapy Blenrep's increase in overall survival in the DREAMM-7 trial has achieved statistical significance
PharmaVoice
NOVEMBER 14, 2024
While Martin Shkreli smirked his way through a public securities fraud investigation, Ron Tilles became interim CEO of Turing Pharmaceuticals, ready or not. Here’s his story.
pharmaphorum
NOVEMBER 14, 2024
There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy. Now, the company has made a move to try to make sure it isn't left behind. Its solution is a licensing deal with Chinese biotech LaNova Medicines for LM-299, which consists of an anti-VEGF antibody joined to the functional parts of a pair of anti-PD-1 antibodies.
European Pharmaceutical Review
NOVEMBER 14, 2024
BioNTech SE has agreed to acquire Biotheus and will gain rights to the biotech’s in-house bispecific antibody drug conjugate (ADC) capability and pipeline candidates. Specifically, BioNTech will obtain worldwide access to the late-stage PD-L1 x VEGF-A-targeting bispecific antibody BNT327/PM8002. This treatment, in combination with BNT325/DB-1305, a Trophoblast Cell-Surface Antigen 2 (“TROP2”)-targeted ADC candidate is being evaluated in an ongoing Phase I/II clinical trial.
pharmaphorum
NOVEMBER 14, 2024
Syncona launches Slingshot Therapeutics with a mission to find promising projects in academia and translate them into development projects.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Pharmaceutical Technology
NOVEMBER 14, 2024
Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.
Nixon Gwilt Law
NOVEMBER 14, 2024
In a significant move to incentivize enhanced primary care delivery and management, the Centers for Medicare & Medicaid Services (CMS) have finalized the Advanced Primary Care Management (APCM) codes in the 2025 Medicare Physician Fee Schedule (the” 2025 Final MPFS” or the “Final Rule”). These codes, proposed earlier this year as part of a broader commitment to expanding primary care management services, are intended to support practices transitioning toward value-based care (See our overvie
Pharmaceutical Technology
NOVEMBER 14, 2024
The US Food and Drug Administration (FDA) has granted accelerated approval for PTC Therapeutics’ KEBILIDI, the first gene therapy in the US that is directly delivered to the brain.
PharmExec
NOVEMBER 14, 2024
Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.
Referral MD
NOVEMBER 14, 2024
Enhancing the Patient Experience in Healthcare Introduction: The patient experience is a cornerstone of successful healthcare, and patient intake forms are often the first point of interaction. Recent trends in patient intake aim to streamline the process, improve accuracy, and enhance patient satisfaction. In this post, we’ll explore these trends and their impact on healthcare practices, highlighting ReferralMD’s innovative solutions in this space.
PharmExec
NOVEMBER 14, 2024
Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Copyright Clearance Center
NOVEMBER 14, 2024
November 14, 2024 – Danvers, Mass. – CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, announced today that it has earned three 2024 Top Workplaces Culture Excellence Awards from human resource technology and research company Energage LLC for Employee Well-Being, Professional Development, and Appreciation. The Top Workplaces Culture Excellence Awards recognize organizations prioritizing people-first cultures and workplace experiences.
PharmExec
NOVEMBER 14, 2024
Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Contrarian Sales Techniques
NOVEMBER 14, 2024
Why Product Knowledge Is the Foundation of Successful Sales In Malaysia’s competitive market, being able to speak confidently and knowledgeably about your product is more than a nice-to-have—it’s a necessity. Product knowledge is what separates a trusted advisor from just another salesperson. In today’s market, Malaysian clients expect more than a basic sales pitch.
Pharmaceutical Technology
NOVEMBER 14, 2024
Discover the top sales and marketing intelligence solutions tailored for the pharmaceutical industry. Download our guide to predictive analytics and data-driven insights.
Contrarian Sales Techniques
NOVEMBER 14, 2024
Why Growing Your Medical Sales Team Is Crucial In the competitive world of healthcare sales, having a skilled, motivated team can make a dramatic difference. A strong sales team not only drives revenue but also strengthens client relationships, builds brand trust, and adapts to evolving industry demands. To effectively grow your medical sales team, you need more than just hiring—you need strategic planning, training, and a clear growth pathway.
PharmaTimes
NOVEMBER 14, 2024
Therapy shows high efficacy in initial trial phase
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
287 
Let's personalize your content